MHC class II‐deficient mice allow functional human CD4 + T‐cell development
European Journal of Immunology · 2023
DOI: 10.1002/eji.202250313 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2023. Verfasst von Fabienne Läderach und 8 weiteren Autor:innen. Beteiligte Einrichtung: Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Research Switzerland.
Abstract (Originalsprache)
Humanized mouse models have been developed to study cell‐mediated immune responses to human pathogens in vivo. How immunocompetent human T cells are selected in a murine thymus in such humanized mice remains poorly explored. To gain insights into this mechanism, we investigated the differentiation of human immune compartments in mouse MHC class II‐deficient immune‐compromised mice (humanized Ab0 mice). We observed a strong reduction in human CD4 + T‐cell development but despite this reduction Ab0 mice had no disadvantage during Epstein–Barr virus (EBV) infection. Viral loads were equally well controlled in humanized Ab0 mice compared to humanized NSG mice, and improved T‐cell recognition of autologous EBV‐transformed B cells was observed, especially with respect to cytotoxicity. MHC class II blocking experiments with CD4 + T cells from humanized Ab0 mice demonstrated MHC class II restriction of lymphoblastoid cell line recognition. These findings suggest that a small number of CD4 + T cells in humanized mice can be solely selected on human MHC class II molecules, presumably expressed by reconstituted human immune cells, leading to improved effector functions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
ORCID-Profile: Christian Münz
Förderung
- Cancer Research Switzerland
Zitieren
APA
Läderach, F., Zdimerova, H., Rieble, L., Schuhmachers, P., Engelmann, C., Valencia-Camargo, A. D., Kirchmeier, D., Böni, M., & Münz, C. (2023). MHC class II‐deficient mice allow functional human CD4 + T‐cell development. European Journal of Immunology. https://doi.org/10.1002/eji.202250313
Vancouver
Läderach F, Zdimerova H, Rieble L, Schuhmachers P, Engelmann C, Valencia-Camargo AD, et al. MHC class II‐deficient mice allow functional human CD4 + T‐cell development. European Journal of Immunology. 2023. doi:10.1002/eji.202250313
BibTeX
@article{Lderach2023,
author = {Läderach, Fabienne and Zdimerova, Hana and Rieble, Lisa and Schuhmachers, Patrick and Engelmann, Christine and Valencia-Camargo, Alma Delia and Kirchmeier, Daniel and Böni, Michelle and Münz, Christian},
title = {MHC class II‐deficient mice allow functional human CD4 + T‐cell development},
journal = {European Journal of Immunology},
year = {2023},
doi = {10.1002/eji.202250313}
}
EUVIMED